S&P 500   3,777.01 (-0.37%)
DOW   30,247.52 (-0.23%)
QQQ   280.61 (-0.54%)
AAPL   145.80 (-0.21%)
MSFT   248.33 (-0.22%)
META   138.18 (-1.50%)
GOOGL   100.81 (-0.82%)
AMZN   120.62 (-0.39%)
TSLA   239.06 (-4.16%)
NVDA   130.90 (-0.58%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.59 (-0.46%)
T   15.92 (-1.06%)
MU   54.53 (+1.06%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.58 (+0.06%)
DIS   99.98 (-1.44%)
AMC   7.32 (-6.51%)
PYPL   93.77 (+1.06%)
PFE   44.09 (-0.83%)
NFLX   233.92 (-2.83%)
S&P 500   3,777.01 (-0.37%)
DOW   30,247.52 (-0.23%)
QQQ   280.61 (-0.54%)
AAPL   145.80 (-0.21%)
MSFT   248.33 (-0.22%)
META   138.18 (-1.50%)
GOOGL   100.81 (-0.82%)
AMZN   120.62 (-0.39%)
TSLA   239.06 (-4.16%)
NVDA   130.90 (-0.58%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.59 (-0.46%)
T   15.92 (-1.06%)
MU   54.53 (+1.06%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.58 (+0.06%)
DIS   99.98 (-1.44%)
AMC   7.32 (-6.51%)
PYPL   93.77 (+1.06%)
PFE   44.09 (-0.83%)
NFLX   233.92 (-2.83%)
S&P 500   3,777.01 (-0.37%)
DOW   30,247.52 (-0.23%)
QQQ   280.61 (-0.54%)
AAPL   145.80 (-0.21%)
MSFT   248.33 (-0.22%)
META   138.18 (-1.50%)
GOOGL   100.81 (-0.82%)
AMZN   120.62 (-0.39%)
TSLA   239.06 (-4.16%)
NVDA   130.90 (-0.58%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.59 (-0.46%)
T   15.92 (-1.06%)
MU   54.53 (+1.06%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.58 (+0.06%)
DIS   99.98 (-1.44%)
AMC   7.32 (-6.51%)
PYPL   93.77 (+1.06%)
PFE   44.09 (-0.83%)
NFLX   233.92 (-2.83%)
S&P 500   3,777.01 (-0.37%)
DOW   30,247.52 (-0.23%)
QQQ   280.61 (-0.54%)
AAPL   145.80 (-0.21%)
MSFT   248.33 (-0.22%)
META   138.18 (-1.50%)
GOOGL   100.81 (-0.82%)
AMZN   120.62 (-0.39%)
TSLA   239.06 (-4.16%)
NVDA   130.90 (-0.58%)
NIO   15.91 (-4.90%)
BABA   84.13 (+0.02%)
AMD   67.59 (-0.46%)
T   15.92 (-1.06%)
MU   54.53 (+1.06%)
CGC   3.03 (-3.50%)
F   12.43 (+0.57%)
GE   67.58 (+0.06%)
DIS   99.98 (-1.44%)
AMC   7.32 (-6.51%)
PYPL   93.77 (+1.06%)
PFE   44.09 (-0.83%)
NFLX   233.92 (-2.83%)
NASDAQ:VYNE

VYNE Therapeutics - VYNE News Today

$0.25
+0.01 (+4.17%)
(As of 10/5/2022 01:35 PM ET)
Add
Compare
Today's Range
$0.24
$0.25
50-Day Range
$0.22
$0.46
52-Week Range
$0.22
$1.75
Volume
1,853 shs
Average Volume
195,902 shs
Market Capitalization
$14.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50
Get VYNE Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.



VYNE Media Mentions By Week

VYNE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VYNE
News Sentiment

0.62

0.79

Average
Medical
News Sentiment

VYNE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VYNE Articles
This Week

0

1

VYNE Articles
Average Week

SourceHeadline
MarketBeat logoVYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Up 48.9% in September
americanbankingnews.com - September 28 at 6:28 AM
finance.yahoo.com logoVYNE Therapeutics Inc. (VYNE)
finance.yahoo.com - September 22 at 8:16 PM
msn.com logoVYNE Therapeutics Earnings Perspective: Return On Capital Employed
msn.com - September 9 at 1:10 PM
finance.yahoo.com logoVYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 6 at 9:18 AM
finance.yahoo.com logoVYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 6 at 9:18 AM
finance.yahoo.com logoAll You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to Buy
finance.yahoo.com - August 17 at 3:18 PM
finance.yahoo.com logoVYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 12 at 10:58 AM
finance.yahoo.com logoVYNE Therapeutics Reports Second Quarter 2022 Financial Results
finance.yahoo.com - August 12 at 10:58 AM
finance.yahoo.com logoVYNE Therapeutics Shares Disappointing Data From Atopic Dermatitis Trial
finance.yahoo.com - August 10 at 4:06 PM
seekingalpha.com logoVyne sheds 31% as mid-stage trial for atopic dermatitis candidate fails
seekingalpha.com - August 10 at 10:58 AM
marketwatch.com logoVYNE Therapeutics Shares Tumble Premarket on Study Failure >VYNE
marketwatch.com - August 10 at 10:58 AM
finance.yahoo.com logoVYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
finance.yahoo.com - August 10 at 10:58 AM
apnews.com logoVYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
apnews.com - July 19 at 9:43 AM
finance.yahoo.com logoVYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
finance.yahoo.com - July 19 at 9:43 AM
msn.com logoVYNE Therapeutics Concludes Patient Enrolment in Mid-Stage Study Of Skin Inflammation Candidate
msn.com - June 17 at 4:32 PM
seekingalpha.com logoVYNE Therapeutics rises on ending enrollment in mid-stage trial of itchy skin gel FMX114
seekingalpha.com - June 17 at 4:32 PM
finance.yahoo.com logoVYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
finance.yahoo.com - June 17 at 4:32 PM
morningstar.com logoVYNE Therapeutics Inc - Stock Quote VYNE
morningstar.com - June 15 at 12:19 AM
seekingalpha.com logoJourney Medical Corporation (DERM) CEO Claude Maraoui on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 12:51 PM
finance.yahoo.com logoVYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - May 12 at 10:13 PM
tmcnet.com logoVYNE Therapeutics to Present at LifeSci Partners' Immunology & Inflammation Symposium on May 10th
tmcnet.com - May 6 at 8:51 AM
finance.yahoo.com logoVYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th
finance.yahoo.com - May 6 at 8:51 AM
finance.yahoo.com logoCompanies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky
finance.yahoo.com - May 5 at 2:59 PM
finance.yahoo.com logoVYNE Therapeutics Inc. (VYNE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
finance.yahoo.com - April 28 at 7:51 PM
seekingalpha.com logoVYNE Therapeutics reports positive data from phase 1 trial of atopic dermatitis therapy
seekingalpha.com - April 7 at 5:20 PM
finance.yahoo.com logoVYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114
finance.yahoo.com - April 7 at 5:20 PM
finance.yahoo.com logoVYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
finance.yahoo.com - April 7 at 9:12 AM
finance.yahoo.com logoVYNE Therapeutics Shares Jump On Encouraging Preclinical Data From VYN201 Program In Rheumatoid Arthritis
finance.yahoo.com - March 30 at 3:15 PM
marketwatch.com logoVYNE Therapeutics Sees Positive Data for Rheumatoid Arthritis Treatment
marketwatch.com - March 30 at 10:14 AM
finance.yahoo.com logoVYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis
finance.yahoo.com - March 30 at 10:14 AM
benzinga.com logoRecap: VYNE Therapeutics Q4 Earnings
benzinga.com - March 17 at 11:46 AM
finance.yahoo.com logoVYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - March 17 at 11:46 AM
finance.yahoo.com logoVYNE Therapeutics' BET Inhibitor Shows Encouraging Preclinical Action In Skin Disorder
finance.yahoo.com - March 8 at 2:21 AM
finance.yahoo.com logoVYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo
finance.yahoo.com - March 7 at 7:25 AM
finance.yahoo.com logoVYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference
finance.yahoo.com - March 3 at 8:14 AM
seekingalpha.com logoVYNE Therapeutics reports initial data from phase 1b/2a study of FMX114 for eczema
seekingalpha.com - January 19 at 1:50 PM
finance.yahoo.com logoVYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
finance.yahoo.com - January 19 at 10:44 AM
nasdaq.com logoVYNE Therapeutics Inc Shares Close the Week 32.6% Lower - Weekly Wrap
nasdaq.com - January 17 at 3:47 AM
nasdaq.com logoVYNE Therapeutics Inc Shares Close the Day 12.5% Lower - Daily Wrap
nasdaq.com - January 16 at 2:34 AM
nasdaq.com logoThursday Sector Laggards: Information Technology Services, Drugs
nasdaq.com - January 13 at 4:44 PM
msn.com logoVYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ Deal
msn.com - January 13 at 11:42 AM
seekingalpha.com logoJourney Medical, Vyne Therapeutics jump nearly 15% on topical minocycline assets deal
seekingalpha.com - January 13 at 7:33 AM
nasdaq.com logoVYNE Therapeutics Inc Shares Close the Day 10.8% Higher - Daily Wrap
nasdaq.com - January 4 at 8:46 AM
finance.yahoo.com logoVYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event
finance.yahoo.com - January 3 at 9:38 AM
nasdaq.com logoDo Options Traders Know Something About VYNE Therapeutics (VYNE) Stock We Don't?
nasdaq.com - December 13 at 1:46 PM
benzinga.com logoHC Wainwright & Co. Assumes VYNE Therapeutics at Buy, Announces Price Target of $7
benzinga.com - December 7 at 12:31 AM
investorplace.com logoVYNE Stock Price Predictions: Why One Analyst Sees VYNE Therapeutics Going to $7
investorplace.com - December 6 at 12:02 PM
finance.yahoo.com logoVYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
finance.yahoo.com - November 18 at 8:51 AM
finance.yahoo.com logoVYNE Therapeutics (NASDAQ:VYNE) investors are sitting on a loss of 80% if they invested a year ago
finance.yahoo.com - November 12 at 2:48 PM
benzinga.com logoVYNE Therapeutics's Return On Capital Employed Insights
benzinga.com - November 11 at 12:39 PM
Get VYNE Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:VYNE) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.